Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02798211 · ClinicalTrials.gov registry record · Phase 4
Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo
A Phase 4 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 258
- Enrollment target
NCT02798211 is a Phase 4 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 258 participants.
The verdict
NCT02798211, a Phase 4 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 258 participants
- Enrollment target
Study Summary
To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
Interventions
- OTHER Placebo
- DRUG Secukinumab 300 mg
- DRUG Secukinumab 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2016-06-27 |
| Est. Completion | 2018-12-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02798211
The ClinicalTrials.gov registry entry for NCT02798211 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02798211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02798211 about?
NCT02798211 is a clinical study titled "Study to Evaluate the Safety and Efficacy of Secukinumab 300 mg and 150 mg in Adult Patients With Active Psoriatic Arthritis (PsA) After 16 Weeks of Treatment Compared to Placebo". To demonstrate that the efficacy of secukinumab 300 mg at Week 16 was superior to placebo in adult patients with active PsA based on the proportion of patients achieving an American College of Rheumatology 20 (ACR20) response.
What is the current status of trial NCT02798211?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 258 participants. The study started on 2016-06-27. Estimated completion is 2018-12-05.
What interventions are being tested in trial NCT02798211?
The interventions under investigation include: Placebo (OTHER), Secukinumab 300 mg (DRUG), Secukinumab 150 mg (DRUG).
Who is sponsoring clinical trial NCT02798211?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.